rs63750471
Variant summary
Our verdict is Uncertain significance. Variant got 2 ACMG points: 2P and 0B. PM2
The NM_000179.3(MSH6):c.648_649delAGinsTT(p.Asp217Tyr) variant causes a missense change. The variant was absent in control chromosomes in GnomAD project. Variant has been reported in ClinVar as Uncertain significance (★★).
Frequency
Consequence
NM_000179.3 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Uncertain_significance. Variant got 2 ACMG points.
Transcripts
RefSeq
Ensembl
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD4 genome Cov.: 32
ClinVar
Submissions by phenotype
not provided Uncertain:2
Not observed at a significant frequency in large population cohorts (Lek 2016); In silico analysis supports a deleterious effect on protein structure/function; This variant is associated with the following publications: (PMID: 23621914, 26333163, 16940983) -
- -
Hereditary cancer-predisposing syndrome Uncertain:2
The c.648_649delAGinsTT variant is located in coding exon 4 of the MSH6 gene. This alteration results from a deletion of AG and insertion of TT between nucleotide positions 648 and 649, involving amino acid positions 216 and 217. The threonine at codon 216 is unchanged (p.T216T), but the aspartic acid at codon 217 is replaced by tyrosine, an amino acid with dissimilar properties (p.D217Y). In one study of 38 early-onset colorectal cancer patients, the c.648_649delAGinsTT variant was described in a Portuguese patient with rectal cancer at age 45 years and was not observed in 108 control samples (Pinto C et al. Br. J. Cancer 2006;95:752-6). This amino acid position is not well conserved in available vertebrate species. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. -
This missense variant replaces aspartic acid with tyrosine at codon 217 of the MSH6 protein. Computational prediction is inconclusive regarding the impact of this variant on protein structure and function (internally defined REVEL score threshold 0.5 < inconclusive < 0.7, PMID: 27666373). Splice site prediction tools suggest that this variant may not impact RNA splicing. To our knowledge, functional studies have not been performed for this variant. This variant has been reported in an individual affected with an early-onset colorectal cancer (PMID: 16940983). This variant has been identified in 3/247652 chromosomes in the general population by the Genome Aggregation Database (gnomAD). The available evidence is insufficient to determine the role of this variant in disease conclusively. Therefore, this variant is classified as a Variant of Uncertain Significance. -
Endometrial carcinoma;C1833477:Lynch syndrome 5;C5436807:Mismatch repair cancer syndrome 3 Uncertain:1
- -
Hereditary nonpolyposis colorectal neoplasms Uncertain:1
This sequence change replaces aspartic acid, which is acidic and polar, with tyrosine, which is neutral and polar, at codon 217 of the MSH6 protein (p.Asp217Tyr). Information on the frequency of this variant in the gnomAD database is not available, as this variant may be reported differently in the database. This missense change has been observed in individual(s) with colorectal cancer (PMID: 16940983). This variant is also known as c.648A>T; 649G>T (p.T216T;D217Y). ClinVar contains an entry for this variant (Variation ID: 89548). An algorithm developed specifically for the MSH6 gene suggests that this missense change is likely to be tolerated (PMID: 2362191). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. -
Endometrial carcinoma Uncertain:1
- -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at